retatrutide phase 3 2025 triple agonist glp-1 gip glucagon A review of an investigational drug retatrutide, a novel agent for the treatment of obesity | European Journal of Clinical Pharmacology Structural insights into the triple

10.2337/diacare.19.8.843 98

Stocks niche oral compounds like Methylene Blue, SLU-PP-332 and oral TB-500 not commonly available in capsule form

GLP1s effects on endothelial and adipose tissue leading to cardiovascular and neuroprotective effects are areas of particular interest

Phase 2: active escalation (weeks 8 to 24) As doses increase toward the therapeutic range of 8 to 12 mg, heart rate effects become more apparent

Glucagon-like peptide-1 (GLP-1) receptor agonists, widely prescribed for type 2 diabetes and obesity management, are now under investigation for potential neuroprotective effects in Alzheimer's disease

Clinical trials published in The New England Journal of Medicine show Semaglutide supports an average weight loss of 1520%